Ferumoxytol: a silver lining in the treatment of anemia of chronic kidney disease or another dark cloud?

Amy Barton Pai
Adinoyi O Garba
Albany College of Pharmacy and Health Sciences, Albany, New York, NY, USA

Abstract: Intravenous iron therapy is pivotal in the treatment of anemia of chronic kidney disease to optimize the response of hemoglobin to erythropoiesis-stimulating agents. Intravenous iron use in patients with chronic kidney disease is on the rise. Recent clinical trial data prompting safety concerns regarding the use of erythropoiesis-stimulating agents has stimulated new US Food and Drug Administration label changes and restrictions for these agents, and has encouraged more aggressive use of intravenous iron. The currently available intravenous iron products differ with regard to the stability of the iron-carbohydrate complex and potential to induce hypersensitivity reactions. Ferumoxytol is a newer large molecular weight intravenous iron formulation that is a colloidal iron oxide nanoparticle suspension coated with polyglucose sorbitol carboxymethyl ether. Ferumoxytol has robust iron-carbohydrate complex stability with minimal dissociation or appearance of free iron in the serum, allowing the drug to be given in relatively large doses with a rapid rate of administration. Clinical trials have demonstrated the superior efficacy of ferumoxytol versus oral iron with minimal adverse effects. However, recent postmarketing data have demonstrated a risk of hypersensitivity that has prompted new changes to the product information mandated by the Food and Drug Administration. Additionally, the long-term safety of this agent has not been evaluated, and its place in the treatment of anemia of chronic kidney disease has not been fully elucidated.

Keywords: iron, ferumoxytol, oxidative stress, safety, kidney disease

Anemia of chronic kidney disease

Chronic kidney disease (CKD) is a worldwide public health care epidemic. In the US, progression of CKD to end-stage renal disease (ESRD) is predicted to affect 775,000 people by the year 2020. Since the introduction of epoietin alfa in 1990, intravenous iron has been a pivotal component of the management of anemia of CKD, particularly among patients with ESRD receiving hemodialysis. Intravenous iron supplementation is administered to optimize red blood cell production by erythropoiesis-stimulating agents to reach target hemoglobin concentrations in patients with ESRD on hemodialysis. Intravenous iron use in ESRD has increased steadily over the past 10 years. The new prospective payment system (eg, “bundled” payment) was initiated by the Centers for Medicaid and Medicare Services on January 1, 2011. The new bundled payment reimburses hemodialysis units at a composite rate, comprised of dialysis treatment, laboratory services, and drugs, whereas the latter two items were formerly billed separately. Erythropoiesis-stimulating agents are markedly more expensive than intravenous iron products, and recent data have confirmed increased intravenous iron use since implementation of the new prospective payment system. This likely represents a growing
trend towards more aggressive use of intravenous iron products in lieu of more expensive erythropoiesis-stimulating agents to meet Centers for Medicare and Medicaid Services performance measures (hemoglobin 10–12 g/dL). Among the pre-ESRD population (ie, CKD stages 3–5), recent clinical trial data suggesting an unfavorable mortality risk in patients receiving erythropoiesis-stimulating agents, especially with aggressive hemoglobin targeting, has driven a trend of using intravenous iron first-line in this growing population. Further, oral iron is generally poorly tolerated and has limited efficacy.

However, a logistic issue presents itself in this population because intravenous iron cannot be administered as conveniently as in hemodialysis patients who can have intravenous iron administered during their in-center dialysis three times per week. This has created interest in intravenous iron with physicochemical properties that would allow larger doses to be administered less frequently in an outpatient clinic setting and where cost savings could be realized. In summary, the complicated evidence base and reimbursement climate has spurred aggressive intravenous iron use in patients with ESRD as well as CKD and not on dialysis. Thus, it remains critically important to understand the efficacy and safety profiles of newer intravenous iron products. This review addresses the efficacy and safety considerations of ferumoxytol, a newer large molecular weight intravenous iron compound.

**Dysfunctional iron metabolism in anemia of CKD**

An estimated 90% of hemodialysis patients have fluctuating hemoglobin patterns. This hemoglobin variability has been attributed to resistance to erythropoiesis-stimulating agents, characterized by not reaching target hemoglobin goals despite high doses of these agents, eg, >400,000 units of epoietin alfa per month. Resistance to erythropoiesis-stimulating agents is also characterized by blockade of the reticuloendothelial system, impairing iron mobilization. Clinically, blockade of the reticuloendothelial system manifests as high serum ferritin, usually coincident with low saturated transferrin concentrations, indicating impaired mobilization and transfer of iron. Other causes of resistance to erythropoiesis-stimulating agents include chronic oxidative stress and inflammation, and, more recently, upregulation of hepcidin.

Hepcidin is a small peptide hormone induced by proinflammatory cytokines, principally interleukin-6. The hormone acts to sequester iron by activating cell signaling pathways that stimulate ferroportin internalization in hepatocytes acting as a negative regulator of iron absorption and release. Plasma hepcidin concentrations have been found to be elevated in several observational studies of patients with CKD and to increase proportionately along the continuum of CKD. Mitigating sources of inflammation, such as chronic periodontitis, were associated with a significant reduction of prohepcidin, interleukin-6, and C-reactive protein in a small pilot study. No improvement in hemoglobin response was observed after antimicrobial treatment for periodontitis. Thus, although hepcidin is elevated in patients with CKD, its utility as a biomarker to predict response to intravenous iron and erythropoiesis-stimulating agents remains to be elucidated.

**Physicochemical properties of ferumoxytol**

Ferumoxytol is described as an iron oxide nanoparticle with a polyglucose sorbitol carboxymethyl ether coating reportedly designed to minimize immunological sensitivity. Its physicochemical properties result in less free iron in vitro than other available intravenous iron preparations. Ferumoxytol consists of superparamagnetic iron oxide coated with a carbohydrate shell consisting of branched polysaccharides, which helps to isolate bioactive iron from plasma components until the iron-carbohydrate complex enters macrophages in the reticuloendothelial system of the liver, spleen, and bone marrow. The molecular weight of ferumoxytol is estimated to be 731 kDa, with a colloidal nanoparticle diameter of 30 nm. Recently, Jahn et al showed an additional peak for ferumoxytol at smaller nanoparticle sizes (about 11 nm diameter) in a gel permeation chromatography experiment to determine particle distribution by weight for various intravenous iron products. When compared with other parenteral iron products, the relative molecular weight of ferumoxytol is as follows: ferumoxytol > iron dextran > iron sucrose > sodium ferric gluconate (see Table 1). Of these formulations, only ferumoxytol was found to be isotonic in a study comparing the physicochemical properties of ferumoxytol with commercially available products in the US. Free (unbound) iron appearance was measured by ultrafiltration and by the bleomycin-detectable iron assay to determine potential direct donation of free iron to transferrin and free iron potentially available to engage in redox reactions, respectively.

Removal of ferumoxytol by an in vitro hemodialysis circuit was also investigated. The relative iron release, catalytic iron availability, and dialysis removal of these intravenous iron formulations were as follows: ferumoxytol < iron dextran < iron sucrose < ferric gluconate. These data suggest...
Table I Comparison of properties of ferumoxytol and those of other intravenous iron formulations

<table>
<thead>
<tr>
<th>Properties</th>
<th>FMX</th>
<th>FCM</th>
<th>IM±</th>
<th>ID‡</th>
<th>IS</th>
<th>FG</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (Da)</td>
<td>731,000</td>
<td>150,000</td>
<td>150,000</td>
<td>410,000</td>
<td>252,000</td>
<td>200,000</td>
</tr>
<tr>
<td>Carbohydrate shell</td>
<td>Polyglucose sorbitol carboxymethyl ether*</td>
<td>Carboxymaltose</td>
<td>Isomaltoside</td>
<td>Dextran polysaccharide</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median shell/particle diameter (nm)</td>
<td>26.3</td>
<td>23.1</td>
<td>20.5</td>
<td>12.2</td>
<td>8.3</td>
<td>8.6</td>
</tr>
<tr>
<td>Relative catalytic iron release</td>
<td>++</td>
<td>++</td>
<td>+</td>
<td>++</td>
<td>+++</td>
<td>+++</td>
</tr>
<tr>
<td>Relative stability of elemental iron within the carbohydrate shell</td>
<td>High</td>
<td>High</td>
<td>High</td>
<td>Medium</td>
<td>Low</td>
<td></td>
</tr>
<tr>
<td>Relative osmolalities*</td>
<td>Isotonic</td>
<td>Isotonic</td>
<td>N/A</td>
<td>Isotonic†</td>
<td>Hypertonic</td>
<td>Hypertonic</td>
</tr>
<tr>
<td>Administration (intravenous push) rates‡</td>
<td>30 mg/sec</td>
<td>Bolus push</td>
<td>50 mg/min</td>
<td>50 mg (1 mL/min)</td>
<td>20 mg/min</td>
<td>12.5 mg/min</td>
</tr>
<tr>
<td>Maximum single dose a,b,c</td>
<td>510 mg</td>
<td>15 mg/kg</td>
<td>20 mg/kg</td>
<td>20 mg/kg</td>
<td>200 mg</td>
<td>125 mg</td>
</tr>
<tr>
<td>Half-life (hours)</td>
<td>About 15</td>
<td>7–12</td>
<td>5–20</td>
<td>5–20</td>
<td>6</td>
<td>–about 1</td>
</tr>
</tbody>
</table>

Notes: *Balakrishnan et al,13 release of catalytic Fe measured by bleomycin-detectable iron assay in a nonclinical model (5 minutes post injection); †from USP package insert prescribing information; aJahn et al,21 shell particle diameter was measured by dynamic light scattering; d data listed are for low molecular weight iron dextran, unless stated otherwise; package insert/prescribing information states the molecular weight of iron sucrose (Venofer®) to be 34,000–60,000 Da; Pai et al40 showed that nontransferrin bound iron levels were significantly higher in patients on iron sucrose and FG versus ID; dFunk et al41 compared physical and pharmacological properties of FCM with other intravenous iron products [† (Fe ≲ 0.02 µg/mL); ++ (Fe > 0.02 to ≲0.04 µg/mL), +++ (>0.04 µg/mL)]; ‡a modified dextran shell; eBalakrishnan et al,21 low molecular weight iron dextran had a slightly hypertonic osmolality (500 mOsmol/kg); ffree (dialyzable) iron was 0.002% in buffered solution but was elevated by 100× in normal saline (Jahn et al20); gapparent molecular weight as measured by gel permeation chromatography (Jahn et al20).

Abbreviations: FMX, ferumoxytol; FCM, ferric carboxymaltose; IM, iron isomaltoside 1000; ID, iron dextran; FG, ferric gluconate; Fe, iron; iS, iron sucrose; iv, intravenous.

Pharmacokinetics

The recommended dosing for ferumoxytol is 510 mg intravenous initially and a second dose of 510 mg administered 3–8 days later.22 The stability of ferumoxytol enables it to be administered as a rapid intravenous bolus injected at a rate up to 1 mL (30 mg) per second. Previous pharmacokinetic studies of other commonly used intravenous iron compounds have examined changes in the iron pool using conventional measures of iron status, including serum iron and transferrin-bound iron.24 Some studies have used ratios derived from ex vivo analyses of serum samples to determine serum iron versus iron from the iron-carbohydrate complex.25 These methods render the pharmacokinetic profile of the drug difficult to interpret because they do not directly measure the plasma concentration or differentiate disposition of the iron-carbohydrate complex from endogenous iron concentrations. In contrast, plasma ferumoxytol concentrations are determined using a validated, drug-specific, nuclear magnetic resonance assay.26 Due to the superparamagnetic properties of ferumoxytol, this bioanalytical method allows for measurement of iron in the intact drug product before its incorporation into iron stores. Thus, exact determination of the pharmacokinetic profile of ferumoxytol can be made. Ferumoxytol exhibits zero-order or Michaelis-Menten (capacity-limited) pharmacokinetics.27 Thus, handling of the drug by the reticuloendothelial system is saturable and the drug will remain in plasma until such time that the concentration is below the saturation concentration and the reticuloendothelial system can resume handling the drug linearly. A randomized, double-blind, ascending-dose study was conducted in healthy volunteers (n = 41) receiving 1, 2, or 4 mg Fe/kg, and 4 mg Fe/kg administered at different rates, with the half-life of ferumoxytol increased with increasing dose from 9.3 to 14.5 hours but not with increasing rate of injection using a constant dose.28 Clearance also decreased, while the area under the concentration-time curve increased with increasing dose, indicating that handling by the reticuloendothelial system is saturable and that the drug follows zero-order pharmacokinetics. However, in this study, linear (first-order) pharmacokinetic analysis was performed, generating erroneous pharmacokinetic parameters.

In a more recent pharmacokinetic study conducted in 58 healthy volunteers, 510 mg of ferumoxytol was administered in two consecutive doses separated by a 24-hour interval.27 The resulting data suggested that a two-compartment, capacity-limited (zero-order) elimination model was most appropriate. The mean ± standard error population Vmax (maximal elimination rate from plasma) was 14.3 ± 1.3 mg/hour. Because interindividual plasma concentrations showed minimal variability, the final parameter estimates were used to simulate a typical two-dose regimen (2 × 510 mg 24 hours apart) to predict linear pharmacokinetic parameters. The day 2 maximal plasma concentration was 281 µg/mL, consistent with the measured value. The terminal half-life was estimated to be about 15.8 hours.
Efficacy

Clinical trials have shown ferumoxytol to be efficacious in increasing hemoglobin, transferrin saturation, and ferritin in patients with anemia of CKD. In a prospective, open-label, Phase II dose-escalation trial to evaluate the safety and efficacy of ferumoxytol, a two-dose regimen of ferumoxytol was shown to increase hemoglobin and transferrin saturation levels significantly from baseline. In two separate, open-label, randomized, controlled, multicenter Phase III trials in patients with CKD, ferumoxytol significantly increased hemoglobin, transferrin saturation, and ferritin when compared with oral iron. These studies and their key outcomes are summarized in Table 2.

There is a lack of published head-to-head trials comparing ferumoxytol with other intravenous iron formulations. Recently, Strauss et al presented preliminary data comparing the hemoglobin response in patients with CKD treated with ferumoxytol versus iron sucrose in FIRST (the Ferumoxytol Compared to Iron Sucrose Trial). The study included patients with all stages of CKD (Stages 1–5D). One hundred and sixty-two patients were randomized to receive ferumoxytol (n = 80) or iron sucrose (n = 82). Ferumoxytol was administered as two consecutive 510 mg doses, while iron sucrose was administered as 100 mg x 10 doses in hemodialysis patients and 200 mg x 5 doses over 14 days in nondialysis patients with CKD. At the end of the 35-day follow-up period, the patients treated with ferumoxytol and those treated with iron sucrose had similar increases in hemoglobin concentrations (0.84 g/dL versus 0.74 g/dL, respectively, P = 0.515). Subgroup analysis of patients with more severe anemia (hemoglobin 7–9 g/dL) showed that 50% of those receiving ferumoxytol had an increase in hemoglobin ≥ 1 g/dL from baseline versus 40% of those receiving iron sucrose. However, neither standard deviations nor statistical analyses were presented with these data.

Safety and tolerability

Immunogenicity

Data from Phase II and III clinical trials overall showed a very favorable safety profile for ferumoxytol (Table 2). In a large, randomized, multicenter, double-blind, placebo-controlled, crossover Phase III safety study, 750 patients with CKD were assigned to receive 510 mg of ferumoxytol over 17 seconds followed by the alternative agent (saline as placebo or vice versa) 7 days later. The total number of reported adverse events was 242 for ferumoxytol and 178 for placebo. Serious adverse events were reported for 21 ferumoxytol-treated patients and for 15 placebo-treated patients. Of the total adverse events reported, 95 were considered to be related to treatment, as determined by the site investigator (5.2% for ferumoxytol treatment and 4.5% for placebo). One serious adverse event was documented as being related to ferumoxytol, and was recorded in an 85-year-old male with multiple drug allergies (although notably, allergy to two or more drugs was an exclusion criterion for the study) who experienced severe hypotension, hot flashes, and itching a few minutes after receiving ferumoxytol. Dyspnea was not reported and the patient’s symptoms resolved after administration of subcutaneous epinephrine. After ferumoxytol was approved by the US Food and Drug Administration (FDA) on June 30, 2009, postmarketing reports of serious hypersensitivity reactions, including those of an anaphylactic type, some of which were life-threatening or fatal, began appearing in the literature and in reports to the FDA. It is important to note that patients with multiple drug sensitivities (ie, not just to intravenous iron) were excluded from all Phase II and III trials. Patients with multiple drug allergy syndrome are well known to be at high risk of hypersensitivity reactions to subsequent chemically unrelated drugs.

The product information for ferumoxytol describes the drug as “a superparamagnetic iron oxide coated with polyglucose sorbitol carboxymethyl ether” (Description) and as a “superparamagnetic iron oxide coated with a carbohydrate shell” (Mechanism of Action). Data published prior to FDA approval contain descriptions of ferumoxytol as an iron oxide core stabilized by carboxymethylated dextran ligands. These data infer that the carbohydrate coating contains branched-chain polysaccharides that may be associated with immunogenicity. A recent case report described a 77-year-old woman with stage 4 CKD who had a previous allergic-type reaction to iron dextran 8 months earlier characterized by dyspnea, hypotension, and back pain. Twenty minutes after a single dose of ferumoxytol 510 mg injected over one minute, the patient experienced pruritus on her abdomen and thighs, dyspnea, wheezing, emesis, and tongue swelling. She developed hypotension and required oxygen due to an oxygen saturation drop to about 80%. Laboratory measurement of tryptase, a marker of mast cell activation, was elevated to 22.9 ng/mL (normal < 11.5 ng/mL), providing compelling evidence that this was an anaphylactoid-type reaction. Bailie et al recently analyzed data obtained via the FDA Freedom of Information Act regarding adverse events reported to the FDA during the period from June 2009 to October 2010 for all available intravenous iron products available in the US. These included iron sucrose (Venofer®), sodium ferric gluconate (Ferrlecit®), high molecular weight...
### Table 2 Summary of safety and efficacy data from key clinical trials

<table>
<thead>
<tr>
<th>Authors</th>
<th>Study type</th>
<th>Patient characteristics</th>
<th>Treatment groups</th>
<th>Outcome at follow-up</th>
<th>P value&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Reported adverse events</th>
</tr>
</thead>
<tbody>
<tr>
<td>Spinowitz et al&lt;sup&gt;20&lt;/sup&gt;</td>
<td>Phase II</td>
<td>CKD patients with Hgb ≤ 12.5 g/dL and TSAT ≥ 35% (n = 21)</td>
<td>4 doses of 255 mg FMX (each dose 2–3 days apart)</td>
<td>Hemoglobin: 10.4 ± 1.3 g/dL increased to 11.4 ± 1.2 g/dL</td>
<td>&lt;0.05&lt;sup&gt;a&lt;/sup&gt;</td>
<td>All ADRs were described as mild: constipation</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(n = 10)</td>
<td></td>
<td></td>
<td></td>
<td>Delayed pruritic edematous rash</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Pain at injection site</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>2 doses of 510 mg (each dose one week apart)</td>
<td>TSAT: 21.3% ± 10% increased to 37.2% ± 22.1%</td>
<td>&lt;0.05&lt;sup&gt;a&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td>Spinowitz et al&lt;sup&gt;29&lt;/sup&gt;</td>
<td>Phase III</td>
<td>Patients with CKD with Hgb ≤ 11 g/dL, ferritin ≤ 600 ng/mL, and TSAT ≥ 30% (n = 304)</td>
<td>2 doses of FMX 510 mg IV (about a week apart)</td>
<td>Hgb: increase by 0.82 ± 1.24 g/dL (FMX) versus 0.16 ± 1.02 g/dL (oral iron)</td>
<td>&lt;0.0001</td>
<td>292 patients were included in the safety analysis</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(n = 228)</td>
<td></td>
<td></td>
<td></td>
<td>Treatment-related ADRs: 10.6% (FMX) versus 24% (oral iron)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>The most common ADRs in the FMX group:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Nausea (1.8%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Dizziness (1.8%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Diarrhea (1.4%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Injection site swelling (0.9%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Provenzano et al&lt;sup&gt;30&lt;/sup&gt;</td>
<td>Phase III</td>
<td>CKD stage 5 patients on HD ≥ 90 days, hemoglobin ≥ 11.5 g/dL, ferritin ≤ 600 ng/mL, and TSAT ≥ 30%, and at stable ESA doses for at least 10 days prior to study (n = 230)</td>
<td>2 doses of FMX 510 mg IV (about a week apart)</td>
<td>Hgb: increased by 1.02 ± 1.13 g/dL (FMX) versus 0.46 ± 1.06 g/dL (oral iron)</td>
<td>0.0002</td>
<td>110 patients were included in the safety analysis</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(n = 114)</td>
<td></td>
<td></td>
<td></td>
<td>Treatment-related ADRs: 8.2% (FMX) versus 15.9% (oral iron)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Serious ADRs in the FMX group (n = 54):</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Hypotension (3.7%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Cellulitis (3.7%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>COPD exacerbation (3.7%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Notes:**<sup>a</sup> Significant changes from baseline at follow-up on day-35;<sup>b</sup> significant difference in cumulative Hgb and TSAT of both groups at day 14; this study did not provide the frequency of ADRs;<sup>c</sup> represents only safety data from the randomized phase of this study.

**Abbreviations:** ADR, adverse drug reaction; COPD, chronic obstructive pulmonary disease; HD, hemodialysis; Hgb, hemoglobin; ESA, erythropoiesis-stimulating agents; FMX, ferumoxytol; IV, intravenous; TSAT, transferrin saturation.
iron dextran (Dexferrum®), low molecular weight iron dextran (InFed®), and ferumoxytrol (Feraheme®). Because of the large discrepancy in market share during the study time period (iron sucrose > sodium ferric gluconate > low molecular weight iron dextran > high molecular weight iron dextran > ferumoxytrol), adverse event rates were calculated both as rates per million units of drug sold and per rates per million 100 mg dose equivalents of intravenous iron. A total of 197 reports were submitted to the FDA for intravenous iron during the study period. Of these, 88 (44.7%) cited ferumoxytrol. The highest numbers of reported deaths were with ferumoxytrol (n = 6) and low molecular weight iron dextran (n = 5), and the highest number of reported adverse events cited ferumoxytrol (n = 70). The adverse event rate for ferumoxytrol reported as per million units sold was 50 and rate per million 100 mg dose equivalents of intravenous iron was ten. In comparison, adverse event rates for low molecular weight iron dextran, an agent known to be associated with hypersensitivity reactions, were 4.5 per million units sold and 4.5 per 100 mg dose equivalents. Risk analysis using calculated odds ratios for adverse events classified as deaths, serious adverse events, other major adverse events, or other adverse events clearly showed that ferumoxytrol was associated with the highest risk for adverse events of all types. For example, the odds ratio for ferumoxytrol was 155-fold higher for death than the odds ratio calculated for iron sucrose. There are several limitations to the interpretation of these data, including the Weber effect, a phenomenon which states that the number of reported adverse reactions for a drug increases until the middle to end of the second year of marketing. However, these data do suggest that further evaluation and vigilant monitoring of patients receiving ferumoxytrol is warranted. Post marketing, the product information for ferumoxytrol was modified in November 2010, June 2011, and November 2011 to incorporate additional information into the Warnings and Precautions and Adverse Reactions sections, noting the risk of hypersensitivity reactions and including a requirement to “observe the patient for signs and symptoms of hypersensitivity during and after Feraheme® administration for at least 30 minutes and until clinically stable following completion of each administration”. The current product information still lists the infusion rate at 30 mg per second (510 mg over 17 seconds), and although administration over one minute has been proposed to improve tolerability, the nature of the reaction being anaphylactoid (not requiring IgE activation and can occur with first dose) versus anaphylactic argues against advocating for this extended administration time because the reaction is not dose-related and could occur at anytime during therapy.

**Free iron appearance, oxidative stress, and organ toxicity**

Patients with CKD are considered to be in a chronic inflammatory state. Oxidative stress is a key factor linking inflammation and cellular damage, resulting in development and progression of atypical cardiovascular disease in these patients. Patients with CKD have several risk factors that place them at a higher risk of oxidative stress including age, obesity, diabetes, hypertension, and reduced antioxidant capacity. The hemodialysis process itself also induces oxidative stress, especially via immune activation through dialyzer contact and endotoxin challenge from dialysate. Thus, patients with CKD are at high risk of the deleterious consequences of pro-oxidant stimuli and have reduced intracellular and extracellular defenses to ameliorate free radical damage. Modern intravenous iron formulations have evolved to be comprised of iron oxide cores encased in protective carbohydrate shells. These carbohydrate moieties “shield” the iron core, allowing for safe delivery to the reticuloendothelial system and preventing direct release of iron into the plasma. Free iron is an important regulator of cell signaling in the Fenton-Haber-Weiss reaction whereby ferric iron is reduced to ferrous iron in the presence of hydrogen peroxide, yielding a hydroxide radical, which is a highly reactive oxygen species. Because of potential toxicity, free iron is tightly regulated and has several important physiological roles in the body, including involvement in mitochondrial electron transport, cytochrome P450 activity, and transfer of oxygen by heme. The efficacy of these carbohydrate molecules in shielding iron and preventing iron-based free radical and cytotoxic reactions is variable and dependent on the size of the carbohydrate shell (eg, molecular weight of the iron-carbohydrate shell). Short-term studies indicate all available formulations are capable of generating free unbound iron which is released directly into the circulation from the iron-carbohydrate complex. However, there is a clear relationship between stability of the complex and appearance of free iron, with the likely rank order based on evaluable data being sodium ferric gluconate > iron sucrose > low molecular weight iron dextran > ferumoxytrol = ferric carboxymaltose = iron malside 1000. Production of oxygen-based free radicals from iron-induced redox reactions can damage any tissue, protein, lipid, or RNA/DNA in close proximity of the free radical.
Using both in vitro and in vivo models, Johnson et al investigated the relative renal toxicity profiles of iron sucrose, sodium ferric gluconate, and ferumoxytol in a model of acute renal failure. In isolated human kidney proximal tubule cell experiments, doses of elemental iron at 500 µg/mL (relevant to clinically achievable plasma concentrations) were studied to determine the effects of the three different intravenous iron products. Cell viability was significantly reduced by iron sucrose but not by sodium ferric gluconate or ferumoxytol. Release of lactate dehydrogenase, a marker of cytotoxicity, was evaluated in proximal tubule cells incubated for 60 minutes with 2 mg/mL of each of the three products and was found to increase significantly after exposure to iron sucrose and sodium ferric gluconate, but not after exposure to ferumoxytol (P < 0.001 for both agents). In the in vivo studies, 2 mg of each of the intravenous iron products was administered to CD-1 mice which were sacrificed 3 hours following administration, at which time renal tissue and plasma were collected. There were no significant changes in renal monocyte chemoattractant protein (MCP-1) mRNA, a marker stimulated by pro-oxidant signaling, in mice exposed to iron sucrose or sodium ferric gluconate, while ferumoxytol-treated animals were noted to show downregulation of MCP-1 mRNA. Similarly, plasma MCP-1 increased significantly only in mice treated with iron sucrose or sodium ferric gluconate. The same experiment was repeated with evaluation of renal tissue and plasma 18 hours post intravenous iron administration. Renal neutrophil gelatinase-associated lipoprotein and mRNA, markers of acute kidney injury, were noted to be significantly elevated in both the iron sucrose and sodium ferric gluconate groups, with no change observed after exposure to ferumoxytol. Collectively, these data suggest that because ferumoxytol is a robust and stable compound, it may not have a high potential to induce oxidative stress in the kidney.

In contrast with the study by Johnson et al, a recent in vivo study compared 40 mg/kg of ferumoxytol with ferric carboxymaltose, low molecular weight iron dextran, and iron sucrose in rats, evaluating oxidative stress parameters in the liver, heart, and kidneys. Doses of intravenous iron products were administered by tail vein injection every 7 days for a total of five doses, and the animals were sacrificed 24 hours after the last intravenous iron dose. In animals exposed to iron sucrose, low molecular weight iron dextran, and ferumoxytol, hepatic Kupffer cells showed positive Prussian blue staining, indicating intracellular deposition of iron. Low molecular weight iron dextran had more extensive liver deposition, with deposits also observed in hepatocytes and sinusoidal endothelial cells. Serum liver function tests were also noted to be significantly elevated with ferumoxytol and low molecular weight iron dextran treatment as early as 24 hours after the first dose. Beginning on day 15, rats treated with ferumoxytol or low molecular weight iron dextran showed increased urinary protein excretion, and at days 22 and 29, ferumoxytol-treated animals showed significantly higher protein excretion than any of the other intravenous iron treatments. Clinical trials have noted an association between intravenous iron and increased proteinuria, generating concern about use in patients with CKD not on dialysis. Expression of proinflammatory cytokines, ie, tumor necrosis factor alpha and interleukin-6, was increased significantly in immunostained liver and kidney tissue in ferumoxytol-treated animals. Taken together, these studies underscore a need to investigate and understand thoroughly the safety and toxicity profiles of larger molecular weight iron-carbohydrate complexes, such as ferumoxytol, because iron-induced oxidative stress may extend beyond simple dissociation of free iron.

Ferumoxytol is the only commercially available intravenous iron product with an iron oxide core consisting of a colloidal dispersion of nanoparticles ranging from about 11 nm to 30 nm in size. Nanoparticles are known to undergo avid uptake by the reticuloendothelial system, resulting in hepatic, splenic, and lymph node iron accumulation, a characteristic exploited for magnetic resonance imaging. Weisssleder et al examined the pharmacokinetic and toxicity profiles of AMI-25, a superparamagnetic iron oxide nanoparticle formulation similar to ferumoxytol that was labeled with a 59Fe tracer to evaluate tissue disposition in the liver, spleen, kidney, lung, and brain. The compound rapidly accumulated in the liver and was cleared slowly, with a half-life estimated at 3 days. Notably, the authors stated that the average patient would receive 80 mg for magnetic resonance imaging, which would produce liver concentrations estimated at 212 µg/g wet weight, well below the toxic concentrations associated with hepatocellular carcinoma (4000 µg/g) in liver deposition disorders. However, a dose of approximately 1500 mg of this compound (a clinically relevant dose of ferumoxytol) would produce liver concentrations of 4000 µg/g, at least transiently. The biodynamics of iron oxide nanoparticles vary depending on particle diameter, with mean superparamagnetic iron oxide particle diameters of 75 nm and ultrasmall superparamagnetic iron oxide particle diameters of 18 nm. Ultrasmall superparamagnetic iron oxides are often not immediately recognized by the reticuloendothelial system, thus prolonging intravascular half-life. These features, which are unique to superparamagnetic iron oxides like ferumoxytol,
may produce different toxicity profiles, particularly at the cellular level, and warrant further investigation.

**Summary**

Ferumoxytol is a novel intravenous iron formulation approved for iron deficiency in adult patients with chronic kidney disease. The robust stability of the iron-carbohydrate complex allows for rapid intravenous administration of large doses of elemental iron (approximately 500 mg). However, post-marketing FDA reports and cases appearing in the literature have raised significant concern regarding hypersensitivity reactions, likely related to the modified dextran-carbohydrate coating surrounding the iron oxide core. Clinical trial data have reported similar adverse event rates to placebo; however, no study has adequately evaluated other risks, such as iron-induced oxidative stress. Although ferumoxytol is associated with minimal appearance of free iron, in vitro and animal studies suggest higher rates of tissue iron deposition and toxicity relative to other available smaller molecular weight intravenous iron compounds. This may be due in part to its unique colloidal nanoparticle structure. In summary, ferumoxytol is a newer intravenous iron product with demonstrated efficacy. However, safety concerns remain, and the place of ferumoxytol in therapy has not been established.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**


